Homeopathy for treatment of irritable bowel syndrome by Peckham, E.J. et al.
Cochrane Database of Systematic Reviews
Homeopathy for treatment of irritable bowel syndrome
(Review)
Peckham EJ, Nelson EA, Greenhalgh J, Cooper K, Roberts ER, Agrawal A
Peckham EJ, Nelson EA, Greenhalgh J, Cooper K, Roberts ER, Agrawal A.
Homeopathy for treatment of irritable bowel syndrome.
Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD009710.
DOI: 10.1002/14651858.CD009710.pub2.
www.cochranelibrary.com
Homeopathy for treatment of irritable bowel syndrome (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
15DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Homeopathy compared to usual care or placebo, Outcome 1 Global improvement - patients
who improved. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Analysis 1.2. Comparison 1 Homeopathy compared to usual care or placebo, Outcome 2 Feeling unwell. . . . . 27
27CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
28INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iHomeopathy for treatment of irritable bowel syndrome (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Homeopathy for treatment of irritable bowel syndrome
Emily J Peckham1, E Andrea Nelson2, Joanne Greenhalgh3, Katy Cooper4, E Rachel Roberts5, Anurag Agrawal6
1Department of Health Sciences, University of York, Heslington, UK. 2School of Healthcare, University of Leeds, Leeds, UK. 3School
of Sociology and Social Policy, University of Leeds, Leeds, UK. 4School of Health and Related Research (ScHARR), University of
Sheffield, Sheffield, UK. 5Homeopathy Research Institute, London, UK. 6Department of Gastroenterology and Medicine, Doncaster
Royal Infirmary, Doncaster, UK
Contact address: Emily J Peckham, Department of Health Sciences, University of York, ARRC Building, Heslington, YO10 5DD,
UK. emily.peckham@york.ac.uk.
Editorial group: Cochrane IBD Group.
Publication status and date: New, published in Issue 11, 2013.
Review content assessed as up-to-date: 4 February 2013.
Citation: Peckham EJ, Nelson EA, Greenhalgh J, Cooper K, Roberts ER, Agrawal A. Homeopathy for treatment of irritable bowel
syndrome. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD009710. DOI: 10.1002/14651858.CD009710.pub2.
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Irritable bowel syndrome (IBS) is a common, chronic disorder that leads to decreased health-related quality of life and work productivity.
Evidence-based treatment guidelines have not been able to give guidance on the effects of homeopathic treatment for IBS because
no systematic reviews have been carried out to assess the effectiveness of homeopathic treatment for IBS. Two types of homeopathic
treatment were evaluated in this systematic review. In clinical homeopathy a specific remedy is prescribed for a specific condition. This
differs from individualised homeopathic treatment, where a homeopathic remedy based on a person’s individual symptoms is prescribed
after a detailed consultation.
Objectives
To assess the effectiveness and safety of homeopathic treatment for treating IBS.
Search methods
We searched MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, the Cumulative Index to Nursing and Allied
Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED), Cochrane IBD/FBD Group Specialised
Register, Cochrane Complementary Medicine Field Specialised Register and the database of the Homeopathic Library (Hom-inform)
from inception to February 2013.
Selection criteria
Randomised controlled trials (RCTs), cohort and case-control studies that compared homeopathic treatment with placebo, other control
treatments, or usual care, in adults with IBS were considered for inclusion.
Data collection and analysis
Two authors independently assessed the risk of bias and extracted data. The primary outcome was global improvement in IBS. The
overall quality of the evidence supporting this outcome was assessed using the GRADE criteria. We calculated the mean difference
(MD) and 95% confidence interval (CI) for continuous outcomes and the risk ratio (RR) and 95% CI for dichotomous outcomes.
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Main results
Three RCTs (213 participants) were included. No cohort or case-control studies were identified. Two studies published in 1976 and
1979 compared clinical homeopathy (homeopathic remedy) to placebo for constipation-predominant IBS. One study published in
1990 compared individualised homeopathic treatment (consultation plus remedy) to usual care (defined as high doses of dicyclomine
hydrochloride, faecal bulking agents and diet sheets asking the patient to take a high fibre diet) for the treatment of IBS in female
patients. Due to the low quality of reporting in the included studies the risk of bias in all three studies was unclear on most criteria and
high for some criteria. A meta-analysis of two small studies (129 participants with constipation-predominant IBS) found a statistically
significant difference in global improvement between the homeopathic remedy asafoetida and placebo at a short-term follow-up of
two weeks. Seventy-three per cent of patients in the homeopathy group improved compared to 45% of placebo patients (RR 1.61,
95% CI 1.18 to 2.18). There was no statistically significant difference in global improvement between the homeopathic remedies
asafoetida plus nux vomica and placebo. Sixty-eight per cent of patients in the homeopathy group improved compared to 52% of
placebo patients (1 study, N = 42, RR 1.31, 95% CI 0.80 to 2.15). GRADE analyses rated the overall quality of the evidence for the
outcome global improvement as very low due to high or unknown risk of bias, short-term follow-up and sparse data. There was no
statistically significant difference found between individualised homeopathic treatment and usual care (1 RCT, N = 20) for the outcome
“feeling unwell”, where the participant scored how “unwell” they felt before, and after treatment (MD 0.03; 95% CI -3.16 to 3.22).
None of the included studies reported on adverse events.
Authors’ conclusions
A pooled analysis of two small studies suggests a possible benefit for clinical homeopathy, using the remedy asafoetida, over placebo
for people with constipation-predominant IBS. These results should be interpreted with caution due to the low quality of reporting
in these trials, high or unknown risk of bias, short-term follow-up, and sparse data. One small study found no statistically difference
between individualised homeopathy and usual care (defined as high doses of dicyclomine hydrochloride, faecal bulking agents and diet
sheets advising a high fibre diet). No conclusions can be drawn from this study due to the low number of participants and the high risk
of bias in this trial. In addition, it is likely that usual care has changed since this trial was conducted. Further high quality, adequately
powered RCTs are required to assess the efficacy and safety of clinical and individualised homeopathy compared to placebo or usual
care.
P L A I N L A N G U A G E S U M M A R Y
Homeopathy for treatment of irritable bowel syndrome
Irritable bowel syndrome (IBS) is a common chronic disorder characterised by altered bowel habits and abdominal pain, discomfort,
bloating, constipation or diarrhoea or both. It is difficult to treat because no single cause has been identified. IBS impairs health-
related quality of life and work productivity. Currently there is no agreement on the best form of treatment for IBS. Therefore it
is important to evaluate the effectiveness and safety of treatments, including homeopathic treatment, which some IBS sufferers use.
Clinical homeopathy matches a ’remedy’ to a specific condition (such as arnica for bruising), whereas individualised homeopathy
involves a series of in-depth consultations to assess symptoms, the effects of remedies and other issues that may affect the patient, in order
to select appropriate ’remedies’. Individualised homeopathy includes both a consultation and a remedy, whereas clinical homeopathy
consists of a remedy without the in-depth consultation.
This review identified three randomised controlled trials (RCTs) including a total of 213 participants. Two RCTs (129 participants)
compared a homeopathic remedy to a placebo remedy for the treatment of constipation-predominant IBS. The other study (23
participants) compared individualised homeopathic treatment (consultation plus remedy) to usual care in female patients diagnosed
with IBS. Usual care consisted of high doses of dicyclomine hydrochloride (an antispasmodic drug) and faecal bulking agents (e.g.
foods high in fibre). Patients in the usual care group received diet sheets asking them to take a high fibre diet. The three trials tested
the effects of homeopathic treatment on the severity of IBS symptoms. None of the included studies reported on side effects. The
RCT comparing individualised homeopathic treatment to usual care found no statistically significant difference between homeopathic
treatment and usual care. No conclusions can be drawn from this study due to the small number of participants and the low quality of
reporting in this trial. In addition, this study was carried out in 1990 and usual care for IBS may have changed since then. Therefore
it is not known how individualized homeopathic treatment performs when compared with current usual care. A pooled analysis of
two small studies (129 participants) suggests a possible benefit for clinical homeopathy, using the remedy asafoetida, over placebo for
people with constipation-predominant IBS at a short-term follow-up of two weeks. However both of the studies were carried out in
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the 1970s when the reporting of trials was not as comprehensive as it is now. These studies were subject to bias which makes it difficult
to determine whether the benefit found in these studies are a true reflection of the effectiveness of homeopathic treatment. Further
high quality RCTs enrolling larger numbers of patients are required to assess the effectiveness and safety of clinical and individualised
homeopathy compared to placebo or usual care.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Homeopathy compared to usual care or placebo for treatment of irritable bowel syndrome
Patient or population: patients with treatment of irritable bowel syndrome
Settings:
Intervention: Homeopathy compared to usual care or placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Homeopathy compared
to usual care or placebo
Global improvement -
patients who improved -
Asafoetida only
Study population RR 1.61
(1.18 to 2.18)
129
(2 studies)
⊕©©©
very low,2,3,4
455 per 10001 732 per 1000
(536 to 991)
Global improvement -
patients who improved -
Asafoetida + nux vom
Study population RR 1.31
(0.8 to 2.15)
42
(1 study)
⊕©©©
very low,5,6,7
522 per 1000 683 per 1000
(417 to 1000)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control group risk estimates come from the control arm of the meta-analysis based on included trials.
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2 The quality of reporting in these studies does not meet current accepted standards making it difficult to assess the overall risk of bias.
However there is a high risk of bias due to selective reporting in Rahlfs 1979 and most bias items were rated as unknown for both
studies.
3 Rahlfs 1976 and Rahlfs 1979 reported outcomes at two weeks. Given the long term nature of IBS it is not clear how useful a two week
outcome is for patients’ and clinicians’ decision making.
4 The sample size is less than the optimal sample size. Sparse data (76 events).
5 The quality of reporting in this study does not meet current accepted standards making it difficult to assess the overall risk of bias.
Downgraded due to unknown risk of bias.
6 This study is reporting outcomes at two weeks. Given the long term nature of IBS it is not clear how useful a two week outcome is for
patients’ and clinicians’ decision making.
7 The sample size is less than the optimal sample size. Sparse data (25 events).
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B A C K G R O U N D
Description of the condition
Irritable bowel syndrome (IBS) is a common, chronic disorder that
affects 10 to 22% of the population in the UK (Williams 2007).
There are an estimated 240,000 primary care consultations for
new cases of IBS per year in the UK (Ehlin 2003). The economic
costs of IBS in primary care in the UK are estimated to be over
GBP 200 million per year (Akehurst 2002). It is difficult to treat
because no single cause has been identified. Treatment is directed
at controlling symptoms, using pharmacological and non-phar-
macological approaches (Spiller 2007; Zijdenbos 2009; Ruepert
2011).
IBS is characterised by recurrent symptoms (i.e. abdominal pain
or discomfort, bloating, constipation, or diarrhoea) that indicate a
dysfunctional gastrointestinal tract rather than an organic change
or specific diagnosis. It has an uncertain prognosis for recov-
ery (Mearin 2006). Such patients have a plethora of non-colonic
symptoms such as back pain, urinary frequency, and chronic fa-
tigue which can lead to the patient being referred to the wrong spe-
ciality and having inappropriate investigations and even surgery.
This can lower quality of life (Agrawal 2006; Longstreth 2007).
In addition, sleep disturbance and depressed mood are common
in IBS patients.
Diagnosis of IBS can be made using the Rome III criteria
(Drossman 2006; Longstreth 2006), although this is largely a re-
search tool used to allow common reporting standards of symp-
toms in trials and other research populations. In clinical practice
the diagnosis of IBS is largely based on symptoms and should be
positive rather than by exclusion, although the presence of alarm
symptoms (e.g. blood in stool, fever or weight loss) should prompt
further investigations (Spiller 2007). IBS can be characterised into
the following subtypes: IBSwith constipation, IBSwith diarrhoea,
IBS with mixed bowel habits and unspecified.
Usual care for IBS commonly includes advice on lifestyle, includ-
ing diet and stress reduction, possibly combined with medication.
There are a number of different medications used to help treat
IBS: antispasmodic medicines, which help to reduce abdominal
pain and cramping; laxatives, which help to treat the symptoms
of constipation; anti-motility medicines, which help to treat the
symptoms of diarrhoea, and tricyclic antidepressants, which were
originally designed to treat depression, but also help to reduce the
feeling of abdominal pain and cramping. Alternative treatments
such as hypnotherapy, psychotherapy and acupuncture have been
tried and have a place in selected patients (Agrawal 2006). How-
ever these treatments have limited availability and are expensive
and labour intensive. Despite much research into both psycholog-
ical and pharmacological treatments for irritable bowel syndrome
no consensus exists on its optimal treatment (Zijdenbos 2009;
Ruepert 2011).
Description of the intervention
Homeopathy is a popular, albeit controversial formof complemen-
tary and alternative medicine. A UK survey has shown that 1.9%
of the population consulted a homeopath in the 12 months prior
to the survey and 8.6% had bought an over-the-counter homeo-
pathic remedy (Thomas 2001). Homeopathy is based on treating
patients with remedies prepared from substances that have been
highly diluted and succussed (shaken). It was first developed by
Samuel Hahnemann in the 18th century in Germany and works
on the principle of “like cures like”whereby a substance that would
cause symptoms in a healthy person cures those same symptoms
in illness.
Homeopathic treatment varies among different practitioners and
four main types can be identified (Linde 1997):
• Individualised (or classical) homeopathy, the type most
commonly practised in the UK, involves a consultation followed
by the prescription of a homeopathic medicine individualised to
the patient;
• Clinical homeopathy, where the same homeopathic
medicine is used for a group of patients all presenting with the
same clinical condition (e.g. lycopodium for IBS, arnica for
bruising);
• Complex homeopathy, where a number of different
homeopathic medicines are given either in a fixed combination
or concurrently; and
• Isopathy, where the homeopathic medicine is based on the
substance which has led to the problem (e.g. grass pollen for hay
fever).
Homeopathic medicines when prescribed by trained professionals
are generally regarded as safe (Dantas 2000).
How the intervention might work
Homeopathy is based on the ‘law of similars’ i.e. a substance which
causes symptoms in a healthy individual can be used to treat sim-
ilar symptoms in a diseased person (Vithoulkas 1980).There is
significant debate regarding the scientific basis for homeopathy
amongst healthcare practitioners, scientists, politicians and policy
makers and the mechanism by which homeopathic remedies may
work is not completely understood.
The manufacture of homeopathic medicines involves serial dilu-
tion alternating with violent agitation (i.e. ‘succussion’). The com-
binationof these twoprocesses is referred to as ‘potentisation’ or ‘se-
quential kinetic activation’ (Gariboldi 2009). Many homeopathic
medicines are diluted beyond Avogadro’s number and therefore
fall under the classification of ultra-high dilutions (UHDs). Avo-
gadro’s number is the number of molecules in a mole of a sub-
stance, approximately 6.0225 × 1023, which means that a sample
diluted beyond 1024 would have reached a stage where it is very
unlikely that there is even a single molecule of the original sub-
stance present. The biological efficacy of UHDs may be depen-
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dent on sequential kinetic activation (Gariboldi 2009), but the
mechanism by which sequential kinetic activation enables a UHD
to be biologically active is unknown. A common theory is that it
involves stable water structures, created by interactions between
molecules of the biological material and the water it is dissolved
in, allowing the water to retain information about the biological
material (Montagnier 2009).
Why it is important to do this review
Lower gastrointestinal tract disorders account for one in 20 of all
general practice consultations in the UK (Thompson 2000). In
addition, gastroenterology problems are the fourth most common
referral to National Health Service (NHS) homeopathic hospi-
tals (Spence 2005) and one of the eight most common conditions
treated by NHS homeopaths in general practice (Mathie 2006).
People with IBS are also more likely to use alternative medicine
than people with upper gastrointestinal disorders or Crohn’s dis-
ease (Smart 1986).The frequencywith which people with IBS con-
sult homeopaths may be some indication of the value which they
place on the homeopathic approach. Homeopathic treatment may
offer a treatment strategy for patients with IBS, but at present it
is not clear if it offers any benefit.
O B J E C T I V E S
The objective of this systematic review is to assess the effectiveness
and safety of homeopathic treatment for IBS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing homeopathic
treatment with placebo or active comparators were considered for
inclusion regardless of blinding method, publication status and
language of publication. Quasi randomised studies were also con-
sidered for inclusion, where allocation was achieved by ’quasi-ran-
dom’ methods such as alternation between treatment arms, year of
birth, month entered into study. Cohort and case-control studies
were also considered for inclusion.
Types of participants
All trials of patients with a diagnosis of IBS were eligible for in-
clusion in this review regardless of age, gender, race, educational
status or duration of IBS. Trials which included IBS patients in
whom 10% or more had unstable psychiatric disorders, ulcerative
colitis, Crohn’s disease, bowel cancer and pregnant and breastfeed-
ing women were excluded from this review.
Types of interventions
Trials were included if one of the groups in the trial received any
type of homeopathic treatment involving the delivery of a home-
opathic remedy (either by a homeopath following a consultation
or studies where a homeopathic remedy was delivered without a
consultation) and the other received placebo, an active comparator
treatment, or no treatment.
Types of outcome measures
All trials that included any one of the following outcome measures
were included in the review.
Primary outcomes
The primary outcome was global improvement of symptoms (pa-
tient-reported or clinician-evaluated or both) as measured by a
global IBS symptom score (e.g. IBS Severity Scoring System, Ad-
equate Relief Measure, GI Symptom Rating Scale, Functional
Bowel Disorder Severity Index or IBS Symptom Questionnaire).
Secondary outcomes
Secondary outcomes included:
• Quality of life as measured by validated quality of life
measure e.g. EQ5D, SF36, IBS Quality of Life Measure, IBS
Quality of Life Questionnaire, Functional Digestive Disorder
Quality of Life Questionnaire, IBS Health Related Quality of
Life Questionnaire;
• Abdominal pain, discomfort and distension;
• Stool frequency, bowel transit time;
• Stool consistency; and
• Adverse events.
Search methods for identification of studies
Electronic searches
The following electronic databases were searched from inception
to February 2013:
The Cochrane Central Register of Controlled Trials (CENTRAL)
on the Cochrane Library, Ovid MEDLINE, EMBASE classic +
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EMBASE, theCumulative Index toNursing andAlliedHealth Lit-
erature (CINAHL) and the Allied and Complementary Medicine
Database (AMED). The Cochrane IBD/FBD Group Specialised
Register and the Cochrane Complementary Medicine Field Spe-
cialised Register were also searched.
MEDLINE was searched with the following terms which can be
applied to other databases:
#1 colonic diseases/OR irritable bowel syndrome/OR colonic dis-
eases, functional/ OR irritable bowel[tw] OR irritable colon[tw]
OR spastic colon[tw] OR functional bowel disease*[tw] OR func-
tional colonic disease*[tw]
#2 homeopathy/ OR homeopath*[tw] OR homoeopath*[tw]
#3 #1 AND #2
Searching other resources
1. Reference searching
The reference lists for all identified studies were inspected for ad-
ditional studies.
2. Conference abstracts
Conference abstracts fromDigestive Disease Week (DDW) 2009-
2010 were searched.
3. Personal contact
The first author of each included study was contacted for infor-
mation regarding unpublished trials.
4. Handsearching
The Homeopath and Homeopathic Links journals were hand-
searched between 2008 - 2011 to determine the likely yield of
these journals.
Data collection and analysis
Selection of studies
Two authors (EJP and ERR) independently reviewed the titles and
abstracts of the studies identified by the literature search. Included
studies were assessed against the predefined inclusion criteria.
Data extraction and management
Two authors (EJP and ERR) independently extracted data from
the included studies. Authors were contacted to clarify any unclear
data.
Assessment of risk of bias in included studies
Two authors (EJP and ERR) independently assessed the method-
ological quality of included randomised trials using the Cochrane
risk of bias tool (Higgins 2011). The following itemswere assessed:
• sequence generation (i.e. was allocation sequence
adequately generated?);
• allocation sequence concealment (i.e. was allocation
adequately concealed?);
• blinding (i.e. was knowledge of the allocated interventions
adequately prevented during the study?);
• incomplete outcome data (i.e. were incomplete outcome
data adequately addressed?);
• selective outcome reporting (i.e. are reports of the study free
of suggestion of selective outcome reporting?); and
• other potential sources of bias (i.e. was the study apparently
free of other problems that could lead to a high risk of bias e.g.
baseline imbalances, evidence of carry-over in cross-over trials,
comparability of groups in cluster trials).
It was intended that, based on these criteria the studies would be
subdivided into three categories:
1. Low risk of bias i.e. all quality criteria met;
2.Medium risk of bias i.e. one or more of the quality criteria partly
met; and
3. High risk of bias i.e. one or more of the quality criteria not met.
It was intended that the quality of quasi-randomised trials, non-
randomised trials, cohort and case control studies would be as-
sessed using a quality instrument designed for assessing the quality
of non-randomised studies (Downs 1998).
Measures of treatment effect
Review Manager (RevMan 5.2) was used to analyse the data. For
continuous outcomes the mean difference (MD) with 95% con-
fidence interval (95% CI) was calculated. For each dichotomous
outcome the risk ratio (RR) with 95% CI was calculated.
Unit of analysis issues
We did not anticipate any unit of analysis issues arising from clus-
ter randomisation. In the case of multiple intervention groups
each intervention group was analysed separately against the con-
trol group and the sample size for the control group was divided
proportionately across each intervention group. We noted that if
the results were reported at multiple time points in the studies,
each outcome would be analysed at pre-defined periods of follow-
up in separate meta-analyses. Time points would be grouped as
follows: less than three months, three months to one year, longer
than one year. These time points were chosen as representing time
frames in which a difference in the likelihood of responding could
be expected.
Dealing with missing data
We intended to analyse data using the intention to treat (ITT)
principle and sensitivity analyses were to be undertaken as appro-
priate (e.g. ITT versus available case, and study quality). However,
data were analysed on an available case basis as the included studies
did not provide enough detail to allow for an ITT analysis.
8Homeopathy for treatment of irritable bowel syndrome (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of heterogeneity
Statistical heterogeneity was assessed using the Chi2 test and the
I2 statistic. The Chi2 test was considered statistically significant
if P ≤ 0.10. If heterogeneity existed between studies (I2 ≥ 50%)
for the primary outcome, reasons for the heterogeneity would be
explored. Clinical heterogeneity would be assessed through the
description of the setting and homeopathic approach used in each
study.
Assessment of reporting biases
In the protocol we noted that if more than 10 studies were iden-
tified for inclusion in this review, funnel plots would be used to
assess publication biases.
Data synthesis
Data from individual trials were combined by meta-analysis if
the interventions, outcomes and patient groups were sufficiently
similar (determined by consensus). For continuous data the mean
difference with 95% CI was calculated where the same scales have
been used. Where studies were deemed sufficiently similar but
different scales have been used the standardised mean difference
would be used to combine data. For dichotomous outcomes the
pooled risk ratio and 95% CI were calculated.
In the protocol we specified that data would not be pooled for
meta-analysis if a high degree of heterogeneity (I2 > 75%) was
detected. A fixed-effect model would be used to pool data in the
absence of heterogeneity. An I2 ≥ 50% is considered to represent
moderate heterogeneity and in such cases (I2 50 to75%) a random-
effects model would be used for pooling the data.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was planned between studies that prospectively
identified IBS patients using ROME III criteria versus studies that
did not use ROME III criteria to prospectively identify IBS pa-
tients. In the protocol we also noted that if data were reported
separately for the different forms of IBS then a subgroup analysis
comparing the different forms would be carried out. A subgroup
analysis was also planned for quasi and true randomisation, differ-
ent comparators (e.g. no treatment, usual care, placebo, or other
active treatment) and different homeopathy interventions (e.g. in-
dividualised or clinical homeopathy).
Sensitivity analysis
In the protocol we noted that if a sufficient number of trials were
identified a sensitivity analysis would be carried out by study qual-
ity to determine if the results of the primary analysis change ac-
cording to which trials are incorporated into the analysis.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies and Characteristics of ongoing studies.
Results of the search
Figure 1 shows details of the search and selection process. From
269 citations initially identified, 29 full text sources were exam-
ined (after removal of duplicates and assessment of abstract), 25
studies were excluded for various reasons (listed in the excluded
studies table) and 3 studies plus one secondary publication from
an included studywere included in the review (Rahlfs 1976; Rahlfs
1979; Owen 1990) . Two studies were included in quantitative
synthesis (Rahlfs 1976; Rahlfs 1979). One ongoing study was also
identified (Peckham 2012).No cohort or case-control studies were
identified.
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Figure 1. Study flow diagram.
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Included studies
Three studieswith a total of 213participantswere included (Rahlfs
1976; Rahlfs 1979; Owen 1990). See Characteristics of included
studies. Owen 1990 was conducted in the UK and published in
English. Rahlfs 1976 and Rahlfs 1979 were conducted in the for-
mer Federal Republic of Germany and published in German and
were translated from German into English. Rahlfs 1976, was a
three arm trial comparing asafoetida against asafoetida + nux vom-
ica, against placebo, whereas Rahlfs 1979 compared asafoetida ver-
sus placebo (the participants in the two trials are independent).
The authors noted that Rahlfs 1976 failed to recruit its target num-
ber of participants, hence the (simplified) trial being re-run. There
were 23 participants inOwen 1990, 72 participants inRahlfs 1976
and 119 participants in Rahlfs 1979. All included studies were
published as full articles.
Owen 1990 compared individualised homeopathic treatment
which involved a homeopathic consultation and an individualised
homeopathic remedy to usual care which consisted of high doses of
dicyclomine hydrochloride, faecal bulking agents and diet sheets
asking the patient to take a high fibre diet. This study differs from
other pragmatic trials of individualised homeopathic treatment,
where the more common approach has been to compare individ-
ualised homeopathic treatment plus usual care to usual care alone.
In Owen 1990 participants were asked to rate how unwell they
felt before and after treatment, exact details of how this was scored
are not given. AlthoughOwen 1990 did not include a global mea-
surement of IBS as one of the outcomes, we considered the rating
of how unwell patients felt to provide a global measurement of
the patients’ health. The other outcome measures in Owen 1990
involved the patients choosing their own top four worst symptoms
and grading these on a visual analogue scale, it was not specified
that these symptoms had to be related to IBS, and details of the
symptoms patients chose were not reported are not given, hence
this outcome measure was not included in this review.
Excluded studies
TheCharacteristics of excluded studies table, describes the charac-
teristics of the 25 excluded studies along with the reason for their
exclusion.
Ongoing studies
The Characteristics of ongoing studies describes the characteris-
tics of the ongoing study on individualised homeopathy for the
treatment of IBS.
Risk of bias in included studies
The risk of bias in the included studies for each domain are dis-
cussed below. See results of the risk of bias analysis are summarized
in Figure 2.
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Figure 2. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included study.
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Allocation
Owen1990, Rahlfs 1976 andRahlfs 1979were described as RCTs.
Owen 1990 reported that the participants were stratified and ran-
domised into one of two treatment groups. However, no details
were given about the stratification or how randomisation sequence
was generated. Rahlfs 1976 reported that a chance code was used
for randomisation, although what this entailed and how it was
implemented was not described. Rahlfs 1979 did not report any
information regarding the method of generation of the randomi-
sation code. Rahlfs 1976 and Rahlfs 1979 provided medication in
sequentially numbered drug containers and were rated as low risk
for allocation concealment. Owen 1990 did not describe the pro-
cedure used for allocation concealment and was rated as unclear
for this item.
Blinding
Participants and physicians were not blinded to treatment allo-
cation in the Owen 1990 study as it was not possible to design
a study where patients were not aware of their receiving an indi-
vidualised homeopathic consultation or usual care. Owen 1990
did not report whether other key study personnel were blinded,
or whether outcome assessment was carried out blind. In Rahlfs
1976 and Rahlfs 1979 the study participants and the doctors who
recruited the participants were blinded to allocation by the use
of an identical placebo. In Rahlfs 1979, the participant blinding
was well described. Rahlfs 1976 and Rahlfs 1979 did not report
whether other key study personnel were blinded, or if outcome
assessment was carried out blind.
Incomplete outcome data
The number of patient withdrawals was reported for Owen 1990,
Rahlfs 1976 and Rahlfs 1979. Although Owen 1990 reported the
number of withdrawals and the arm fromwhich the patients with-
drew, the reasons for withdrawal were not reported. Rahlfs 1976
did not report which arms that patients withdrew from and there-
fore it was not clear whether there may be attrition bias in this
trial. Rahlfs 1979 reported the number of withdrawals from each
treatment group and the reasons for withdrawal. Whilst dropouts
appear to be comparable in terms of number and reason for with-
drawal across both arms of this study (Rahlfs 1979), it should be
remembered that any dropout threatens group comparability at
baseline as random allocation seeks to distribute both known and
unknown characteristics across groups, and dropouts may differ
for unknown characteristics that cannot be measured.
Selective reporting
Due to insufficient reporting inOwen 1990 and Rahlfs 1976 both
studies were rated as unclear for the item on selective reporting.
Rahlfs 1979 was deemed to be at a high risk of bias due to selec-
tive reporting because of evidence of selective choice of data for
an outcome. Some participants were excluded from the outcome
analyses for not meeting the inclusion criteria while other partici-
pants who did not meet the inclusion criteria in terms of age were
included in the analyses.
Other potential sources of bias
Due to the low quality of reporting in Owen 1990, Rahlfs 1976
and Rahlfs 1979, the potential for other sources of bias in these
studies could not be assessed.
Effects of interventions
See: Summary of findings for the main comparison
Homeopathy compared to usual care or placebo for treatment of
irritable bowel syndrome
Clinical homeopathic remedy versus placebo remedy
Rahlfs 1976 and Rahlfs 1979 assessed global improvement in IBS
at two weeks as an outcome measure. For this outcome patients
were asked to measure their improvement on a three-point scale
(Rahlfs 1976) and a four-point scale (Rahlfs 1979). For the Rahlfs
1976 study participants were asked to rate whether they were not
or negligibly improved, more than half improved or free of symp-
toms. Participants in the Rahlfs 1979 study were asked to rate
whether they were worse, not or negligibly improved, more than
half improved or free of symptoms. For the purposes of this review,
we dichotomised these scales into two categories: those who had
improved (more than half improved or free of symptoms) versus
those who had not improved (those who were worse, or not or
negligibly improved).
Rahlfs 1976 found no statistically significant difference between
the homeopathic remedy asafoetida and placebo (RR 1.28, 95%
CI 0.78 to 2.10), and no statistically significant difference between
asafoetida plus nux vom and placebo (RR 1.31, 95% CI 0.80 to
2.15). A RR greater than one favours the homeopathic group.
Rahlfs 1979 reported a statistically significant difference between
the homeopathic remedy asafoetida and placebo (RR 1.82, 95%
CI 1.23 to 2.96). A pooled analysis (129 participants) found a
statistically significant difference between the homeopathic treat-
ment asafoetida and placebo. Seventy-three per cent of patients in
the homeopathy group improved at two weeks compared to 45%
of placebo patients (RR 1.61, 95% CI 1.18 to 2.18; See Figure 3).
No heterogeneity was detected for this comparison (P = 0.27; I2
= 18%).
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Figure 3. Forest plot of comparison: 1 Homeopathy compared to usual care or placebo, outcome: 1.1
Global improvement - patients who improved.
Homeopathic treatment versus usual care
InOwen 1990 participants were asked to rate how unwell they felt
before and after treatment. No statistically significant difference
was found between homeopathic treatment and usual care (MD
0.03, 95% CI -3.16 to 3.22; See Figure 4).
Figure 4. Forest plot of comparison: 1 Homeopathy compared to usual care or placebo, outcome: 1.2
Feeling unwell.
Outcome data from theOwen 1990 study was not pooled with the
data from Rahlfs 1976 and Rahlfs 1979 because of heterogeneity
between the studies. The three studies investigated two different
types of homeopathy. Owen 1990 investigated the effectiveness
of individualised (classical) homeopathic treatment, whilst Rahlfs
1976 and Rahlfs 1979 investigated clinical homeopathy. The type
of IBS investigated was also potentially different. In the Owen
1990 study participants were diagnosed with IBS and no further
information on type was given, whilst the participants in Rahlfs
1976 and Rahlfs 1979 had constipation-predominant IBS. In ad-
dition, the studies measured outcomes at different time points.
Owen 1990 measured outcomes at 12 weeks, whilst Rahlfs 1976
and Rahlfs 1979 measured outcomes at 2 weeks. The primary
outcome for the Owen 1990 study was not a global improvement
measure and was not comparable with the other two studies. Al-
though it may be tempting to combine studies in a meta-analysis
when it is likely to yield a statistically significant result, it is im-
portant not to combine studies where there is significant clinical
heterogeneity, because these results would not be meaningful due
to the large degree of differences between the studies. For these
reasons the outcomes from Owen 1990, Rahlfs 1976 and Rahlfs
1979 were not combined.
The secondary outcomes quality of life, abdominal pain, stool
frequency, stool consistency and adverse events were not reported
on in the included studies and therefore it was not possible to
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include them in this review.
D I S C U S S I O N
Summary of main results
Two RCTs compared a clinical homeopathic remedy with placebo
for treating constipation-predominant IBS (Rahlfs 1976; Rahlfs
1979). In a meta-analysis of these studies, the homeopathic rem-
edy was found to be significantly more effective than placebo for
improvement in global IBS symptoms at a short-term follow-up
of two weeks. However, this result should be interpreted with cau-
tion due to the low quality of the reporting in these studies, a high
or unknown risk of bias associated with the trials in this pooled
analysis, short-term follow-up, and sparse data.
One RCT (Owen 1990) compared individualised homeopathic
treatment with usual care for treating women with IBS. No signif-
icant difference was found between individualised homeopathic
treatment and usual care (dicyclomine hydrochloride, faecal bulk-
ing agents, and diet sheets advising a high fibre diet) as measured
by how unwell the participants felt before and after treatment. No
conclusions can be drawn from this study due to the small number
of participants, the low quality of reporting in this trial and a high
risk of bias.
Overall completeness and applicability of
evidence
Rahlfs 1976 and Rahlfs 1979 assessed the effectiveness of clinical
homeopathy for the treatment of constipation-predominant IBS.
Therefore this review does not provide information on the effec-
tiveness of clinical homeopathy for the treatment of IBS in general,
or diarrhoea-predominant, or mixed typology IBS. Both Rahlfs
1976 and Rahlfs 1979 reported outcomes at two weeks. Given
the long term nature of IBS it is not clear how useful a two-week
outcome is for patients’, clinicians’ and policy makers’ decision
making. As people live with IBS for years, an evaluation of impact
at two weeks fails to take into account possible rebound effects or
longer term benefits or adverse events that would be important for
patients and practitioners to know about when they consider the
potential benefits and harms associated with this intervention.
Only one study assessing the effectiveness of individualised home-
opathic treatment was identified in this review (Owen 1990). The
number of participants in this study was small (23) and the study
was conducted over 20 years ago. It is likely that there have been
changes in usual care for IBS since this time, therefore Owen 1990
may not provide a full picture of the effectiveness of individualised
homeopathic treatment compared to usual care. Therefore this
review is unable to conclude anything about the use of individu-
alised homeopathic treatment for IBS.
Quality of the evidence
The results from the pooled analysis indicate a possible benefit for
homeopathic treatment using clinical homeopathy (non-individ-
ualised homeopathic remedies) over placebo for constipation-pre-
dominant IBS. However, this result needs to be interpreted with
caution. The two studies included in the pooled analysis (Rahlfs
1976 and Rahlfs 1979) were carried out in the 1970s before the
introduction of the CONSORT statement (Begg 1996), and the
quality of reporting in these studies does not meet currently ex-
pected standards (Schultz 2010). The low quality of the reporting
means that it is not possible to determine whether or not these
studies were carried out in a rigorous manner and thus how likely
it is that these results are a true reflection of the treatment effect.
Both studies were determined to have an unknown risk of bias for
most assessed items and Rahlfs 1979 was at a high risk of reporting
bias. The quality of the evidence supporting the primary outcome
(i.e. global improvement) was very low due to the low quality of
reporting in the included studies, high or unknown risk of bias,
sparse data and short-term follow-up.
Participants in the Rahlfs 1976 and Rahlfs 1979 studies were re-
cruited through general practice as having suspected IBS. It is not
clear whether diseases such as Crohn’s disease or ulcerative colitis
were ruled out in these participants and it is possible that some
participants had diseases such as Crohn’s or ulcerative colitis rather
than IBS.
The quality of the reporting in the Owen 1990 study was low, and
this study does not meet the current expected standards (Schultz
2010). No conclusions can be drawn from this study due to the
small number of participants and risk of bias. Owen 1990 was
rated as high risk of bias for blinding of participants and personnel.
The study was rated as unknown risk of bias for the other assessed
items. The exact details of the medication prescribed in the usual
care arm, in terms of dosage and frequency was not reported.
Potential biases in the review process
To avoid potential biases in the review process data extraction was
carried out independently by two assessors. In addition, efforts
were made to identify all studies that were potentially eligible for
this review (see Searchmethods for identification of studies).How-
ever, It is possible that not all potentially eligible studies were iden-
tified. This could be because potentially eligible studies have been
carried out and then have not been published, or that studies have
been published but not in places where they could be accessed,
possibly because they were published in little known non-indexed
journals or they could have been published in places where they
should have been found, but were not found. Cohort and case-
control studies were considered for inclusion but none were iden-
tified by the literature search. In retrospect the inclusion of case-
control studies was not appropriate given that the main reason for
including case-control studies in a review is when an event is very
rare and thus it is unlikely that any RCTs have been carried out
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(Reeves 2011).
Agreements and disagreements with other
studies or reviews
No other systematic reviews of homeopathic treatment for IBS
were identified. However non-condition specific systematic re-
views of homeopathic treatment that included the Rahlfs 1976
and Rahlfs 1979 studies have been published (Linde 1997; Shang
2005). Neither of these systematic reviews carried out any analy-
ses on homeopathy for the treatment of IBS or specifically com-
mented on homeopathy for IBS.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In this review of homeopathic treatment for IBS, two of the
included studies used clinical (non-individualised) homeopathic
remedies to treat patients with constipation-predominant IBS
(Rahlfs 1976; Rahlfs 1979). A meta-analysis of these two studies
found a statistically significant benefit favouring the homeopathic
remedy over placebo. However, these results should be interpreted
with caution due to the low quality of reporting in these studies, a
high or unknown risk of bias and sparse data. Thus it is not possi-
ble to be certain whether or not the trials were able to distinguish
between true treatment effects, chance or bias. Furthermore, the
low quality of reporting practice means that it is difficult to assess
whether the results would be replicated in everyday practice, that
is, whether the results are externally valid or generalisable.
It is of note that Rahlfs 1976 and Rahlfs 1979 reported outcomes
at two weeks. Given the long term nature of IBS, it is not clear how
useful a two-week outcome is for decision making. It is essential
that trials have a follow-up period that is clinically meaningful.
As people live with IBS for years, an evaluation of impact at two
weeks fails to take into account any possible rebound effects, or
longer term benefits or adverse events that would be important for
patients and practitioners to know about when they consider the
potential benefits and harms associated with this intervention.
One of the included studies (Owen 1990), found no statistically
significant difference between individualised homeopathic treat-
ment and usual care consisting of dicyclomine hydrochloride and
faecal bulking agents. Individualised homeopathy is themost com-
mon form of homeopathy practised in the UK. However due to
the poor quality of reporting in this study and the small number
of participants in this trial, no conclusions can be made regarding
the usefulness of individualised homeopathic treatment for the
treatment of IBS.
Implications for research
Rahlfs 1976 and Rahlfs 1979 evaluated clinical homeopathy in-
volving pre-specified homeopathic remedies for the treatment of
constipation-predominant IBS and were therefore designed to as-
sess the effectiveness of non-individualised homeopathic remedies.
However due to the high risk of reporting bias in one of these
studies and unclear reporting in both of these studies it is rec-
ommended that these trials are repeated using current reporting
guidelines (Schultz 2010), to determine whether or not there is any
benefit associated with homeopathy for IBS. Future high quality
studies should enrol larger numbers of patients and assess longer
term efficacy and safety outcomes.
Owen 1990 assessed the effectiveness of individualised homeo-
pathic treatment compared to usual care.Due to the lowquality re-
porting in this study and the likelihood that usual care for IBS has
changed since this study was conducted, it is recommended that
the effectiveness and safety of individualised homeopathic treat-
ment be evaluated in a well-designed, adequately powered trial.
A C K N OW L E D G E M E N T S
Funding for the IBD/FBD Review Group (September 1, 2010 -
August 31, 2015) has been provided by the Canadian Institutes of
Health Research (CIHR) Knowledge Translation Branch (CON
- 105529) and the CIHR Institutes of Nutrition, Metabolism
and Diabetes (INMD); and Infection and Immunity (III) and the
OntarioMinistry of Health and Long TermCare (HLTC3968FL-
2010-2235).
Miss Ila Stewart has provided support for the IBD/FBD Review
Group through the Olive Stewart Fund.
The University of Leeds School of Healthcare PhD fellowship
awarded to Emily Peckham supported this work.
16Homeopathy for treatment of irritable bowel syndrome (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Owen 1990 {published data only}
Lecoyte T, Owen D, Shepherd H, Letchworth A, Mullee
M. An investigation into the homeopathic treatment of
patients with irritable bowel syndrome. Proceedings of the
48th LMHI Congress. Vienna, Austria, 1993.
∗ Owen D. An investigation into the homoeopathic
treatment of patients with irritable bowel syndrome.
Congress of the Faculty of Homoeopathy. Windermere,
1990.
Rahlfs 1976 {published data only}
Rahlfs VW, Mossinger P. Treatment of irritable colon.
A multicenter placebo-controlled double-blind study in
general practice [Ein multizentrischer plazebo–kontrollierter
doppelblindversuch in der allgemeinen praxis]. Arzneimittel
Forschung 1976;26(12):2230–4.
Rahlfs 1979 {published data only}
Rahlfs VW, Mossinger P. Asa foetida in the treatment of the
irritable colon; a double blind trial [Asa foetida bei colon
irritabile]. Deutsche Medizinische Wochenschrift 1979;104
(4):140–3.
References to studies excluded from this review
Aleem 2000 {published data only}
Aleem SM. Colo-rectal disorders. National Journal of
Homeopathy 2000;2(4):259–61.
Anonymous 2005 {published data only}
Anonymous. Homeopathy and placebo [Omeopatia e
placebo]. Medico e Bambino 2005;24(7):415.
Anonymous 2009 {published data only}
Anonymous. Homoeopathy associated with improvements
in health. Australian Journal of Pharmacy 2009;90:75.
Bhagat 2010 {published data only}
Bhagat J. Case study and management of irritable bowel
syndrome. Homoeopathic Heritage International 2010;35
(1):18–21.
Bhattacharjee 2010 {published data only}
Bhattacharjee J. Irritable bowel syndrome - a menace in
disguise. Homoeopathic Heritage International 2010;35(1):
34–9.
Chimthanawala 2004 {published data only}
Chimthanawala D. Irritable bowel syndrome - a few cases.
National Journal of Homoeopathy 2004;6(2):102–4.
Diamond 2005 {published data only}
Diamond JA, Diamond JW. Common functional bowel
problems. Advance for Nurse Practitioners 2005;13(5):
31–34,72.
Feldhaus 2000 {published data only}
Feldhaus HW. Comprehensive therapy recommendation for
irritable bowel syndrome [Ganzheitliche therapieempfehlung
bei reizdarm: Behandlungsvorschlag aus unserem
preisratsel]. Arztezeitschrift fur Naturheilverfahren 2000;4
(6):336–7.
Gamble 2007 {published data only}
Gamble J. Case insights series. A study on irritable bowel
syndrome. Similia: Journal of the Australian Homoeopathic
Association 2007;19(1):19–21.
Gebhardt {published data only}
Gebhardt KH. Homeopathy for catarrh of the mucous
membrane of the air routes, intestines and urinary tract
[Homootherapie der schleimhautkatarrhe der luftwege,
speisewege und harnwege]. Erfahrungsheilkunde 1988;37
(4):202–4.
Gray 1998 {published data only}
Gray J. How I treat irritable bowel disease: a survey of
25 patients. British Homoeopathic Journal 1998;87(4):
195–202.
Greeson 2008 {published data only}
Greeson JM, Rosenzweig S, Halbert SC, Cantor IS, Keener
MT, Brainard GC. Integrative medicine research at an
academic medical centre: Patient characteristics and health-
related quality-of-life outcomes. Journal of Alternative and
Complementary Medicine 2008;14(6):763–7.
Innes 2000 {published data only}
Innes MA, Greenfield SM, Hunton M. Using case studies
for prescribing research - an example from homoeopathic
prescribing. Journal of Clinical Pharmacy and Therapeutics
2000;25(6):399–409.
Jagose A {published data only}
Jagose A. The efficacy of homoeopathy in IBS. National
Journal of Homoeopathy 2004;6(2):106–7.
Jones 1996 {published data only}
Jones A. Homoeopathic case studies: irritable bowel
syndrome. Positive Health 1996;16:30.
Jones 1997 {published data only}
Jones A. Irritable bowel syndrome. Homoeopathy 1997;47
(5):101–2.
Jones 1999 {published data only}
Jones A. Homeopathic case studies: Nux Vomica for bowel
symptoms. Positive Health 1999;37:25.
Krishendu 2010 {published data only}
Krishendu. Irritable bowel syndrome - a homeopathic
perspective. Homoeopathic Heritage International 2010;35
(1):26–30.
Lobo 2000 {published data only}
Lobo A. IBS: a constitutional approach. National Journal of
Homoeopathy 2000;2(4):262a–d.
Master 2008 {published data only}
Master FJ. From the editor’s desk. Homoeopatic approaches
to irritable bowel syndrome. Homoeopathic Heritage
International 2008;33(10):4–5.
17Homeopathy for treatment of irritable bowel syndrome (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mohan 2006 {published data only}
Mohan G, Kishore KC, Ratna SA. Irritable bowel syndrome:
“A challenge in medical practice”. National Journal of
Homoeopathy 2006;8(2):131–3.
Pinto 1999 {published data only}
Pinto G. Case studies - Marylebone health centre action
research enquiry. Homoeopath 1999;75:36–41.
Slade 2003 {published data only}
Slade N. Homeopatic casebook. Homeopathy and colitis.
Positive Health 2003;86:25–8.
Turner 2008 {published data only}
Turner R. Homeopathic approaches to irritable bowel
syndrome (IBS). Positive Health 2008;146:18–21.
White 1999 {published data only}
White A. Irritable bowel syndrome. Complementary
Medicine Bulletin 1999;1(6):1–2.
References to ongoing studies
Peckham 2012 {unpublished data only}
Homeopathy for irritable bowel syndrome (HIBS).
Ongoing study January 2011.
Additional references
Agrawal 2006
Agrawal A, Whorwell PJ. Irritable bowel syndrome:
diagnosis and management. BMJ 2006;332(7536):280–3.
Akehurst 2002
Akehurst RL, Brazier JE, Mathers N, O’Keefe C,
Kaltenthaler E, Morgan A, et al. Health-related quality
of life and cost impact of irritable bowel syndrome in a
UK primary care setting. Pharmacoeconomics 2002;20(7):
455–62.
Begg 1996
Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin
I, et al. Improving the quality of reporting randomized
controlled trials The CONSORT statement. JAMA 1996;
276(8):637–9.
Dantas 2000
Dantas F, Rampes H. Do homeopathic medicines provoke
adverse effects? A systematic review. British Homoeopathic
Journal 2000;89(Supplement 1):S35–8.
Downs 1998
Downs SH, Black N. The feasibility of creating a checklist
for the assessment of the methodological quality both of
randomised and non-randomised studies of health care
interventions. Journal of Epidemiology and Community
Health 1998;52(6):377–84.
Drossman 2006
Drossman D. The functional gastrointestinal disorders
and the Rome III process. Gastroenterology 2006;130(5):
1377–90.
Ehlin 2003
Ehlin AG, Montgomery SM, Ekbom A, Pounder RE,
Wakefield AJ. Prevalence of gastrointestinal diseases in two
British national birth cohorts. Gut 2003;52(8):1117–21.
Gariboldi 2009
Gariboldi S, Palazzo M, Zanobbio L, Dusio GF, Mauro
V, Solimene U, et al. Low dose oral administration of
cytokines for treatment of allergic asthma. Pulmonary
Pharmacology and Therapeutics 2009;22(6):497–510.
Higgins 2011
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter
8: Assessing risk of bias in included studies. In: Higgins
JPT, Green S editor(s). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane–handbook.org.
Linde 1997
Linde K, Clausius N, Ramirez G, Melchart D, Eitel F,
Hedges L, et al. Are the clinical effects of homeopathy
placebo effects? A meta-analysis of placebo controlled trials.
Lancet 1997;350(9081):834–43.
Longstreth 2006
Longstreth GF, Thompson WG, Chey WD, Houghton
LA, Mearin F, Spiller RC. Functional bowel disorders.
Gastroenterology 2006;130(5):1480–91.
Longstreth 2007
Longstreth GF. Avoiding unnecessary surgery in irritable
bowel syndrome. Gut 2007;56(5):608–10.
Mathie 2006
Mathie RT, Robinson TW. Outcomes from homeopathic
prescribing in medical practice: A prospective, research-
targeted, pilot study. Homeopathy 2006;95(4):199–205.
Mearin 2006
Mearin F, Badía X, Balboa A, Benavent J, Caballero
AM, Domínguez-Muñoz E, et al. Predictive factors of
irritable bowel syndrome improvement: 1-year prospective
evaluation of 400 patients. Alimentary Pharmacology and
Therapeutics 2006;23(6):815–26.
Montagnier 2009
Montagnier L, Aïssa J, Ferris S, Montagnier JL, Lavallée
C. Electromagnetic signals are produced by aqueous
nanostructures derived from bacterial DNA sequences.
Interdisciplinary Sciences, Computational Life Sciences 2009;1
(2):81–90.
Reeves 2011
Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter
13: Including non-randomized studies. In: Higgins JPT,
Green S editor(s). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane–handbook.org.
Ruepert 2011
Ruepert L, Quartero AO, de Wit NJ, van der Heijden
GJ, Rubin G, Muris JW. Bulking agents, antispasmodics
and antidepressants for the treatment of irritable bowel
syndrome. Cochrane Database of Systematic Reviews 2011,
Issue 8. [DOI: 10.1002/14651858.CD003460.pub3]
18Homeopathy for treatment of irritable bowel syndrome (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schultz 2010
Schulz KF, Altman DG, Moher D, CONSORT Group.
CONSORT 2010 Statement: Updated guidelines for
reporting parallel group randomised trials. Journal of
Clinical Epidemiology 2010;63(8):834–40.
Shang 2005
Shang AJ, Huwiler-Muntene MD, Narety C, Juni P, Dorig
S, Sterne JA, et al. Are the clinical effects of homoeopathy
placebo effects? Comparative study of placebo-controlled
trials of homoeopathy and allopathy. Lancet 2005;366
(9487):726–32.
Smart 1986
Smart HL, Mayberry JF, Atkinson M. Alternative medicine
consultations and remedies in patients with the irritable
bowel syndrome. Gut 1986;27(7):826–8.
Spence 2005
Spence DS, Thompson EA, Barron SJ. Homeopathic
treatment for chronic disease: a 6 year, university-hospital
outpatient observational study. Journal of Alternative and
Complementary Medicine 2005;11(5):793–8.
Spiller 2007
Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L,
Hungin P, et al. Guidelines on the irritable bowel syndrome:
mechanisms and practical management. Gut 2007;56(12):
1770–98.
Thomas 2001
Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on
complementary medicine in England: a population based
survey. Complementary Therapies in Medicine 2001;9(1):
2–11.
Thompson 2000
Thompson WG, Heaton KW, Smyth GT, Smyth C.
Irritable bowel syndrome in general practice: prevalence,
characteristics, and referral. Gut 2000;46(1):78–82.
Vithoulkas 1980
Vithoulkas G. The Science of Homeopathy. New York: Grove
Press, 1980.
Williams 2007
Williams JG, Roberts SE, Ali MF, Cheung WY, Cohen DR,
Demery G, et al. Gastroenterology services in the UK. The
burden of disease, and the organisation and delivery of
services for gastrointestinal and liver disorders: a review of
the evidence. Gut 2007;56 Suppl 1:1–113.
Zijdenbos 2009
Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G,
Quartero AO. Psychological treatments for the management
of irritable bowel syndrome. Cochrane Database of
Systematic Reviews 2009, Issue 1. [DOI: 10.1002/
14651858.CD006442.pub2]
∗ Indicates the major publication for the study
19Homeopathy for treatment of irritable bowel syndrome (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Owen 1990
Methods RCT, unblinded, parallel study, 12 weeks duration
Participants Setting; county hospital, UK
Number of participants; 23 patients were allocated into one of the treatment groups, 20
patients included in analysis
Recruitment methods; female patients attending the out-patient department at a county
hospital in whom a diagnosis of IBS was made
Diagnosis of IBS; clinical diagnosis by a consultant gastroenterologist and consultant
gynaecologist
Age range of patients; 20-69 years
Gender (of treated patients); 100% female
Duration of symptoms > 3 months
Interventions 1. Individualised homeopathic treatment
2. High doses of Dicyclomine hydrocholoride (exact dose not stated), faecal bulking
agents and diet sheets advising a high fibre diet
Outcomes Patients were asked to grade: their four worst symptoms on a visual analogue scale,
dysmenorrhoea, dyspareunia, and feeling unwell at baseline, 2, 6 and 12 weeks
Notes Detailed information is given on the homeopathic treatment the participants received
in terms of; remedy chosen, potency and dosage, whilst no information is given on
the strength and dosage of the dicyclomine hydrocholoride and faecal bulking agents
prescribed in the usual care arm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Although it is stated that this is a ran-
domised trial no details were given as to
how randomisation was achieved
Allocation concealment (selection bias) Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition, whilst
possible reasons for attrition were discussed
for one patient, the reasons for the other
two patients leaving the study were not re-
ported
Selective reporting (reporting bias) Unclear risk Insufficient information is provided to be
able to judge whether the study is at risk
from selective reporting
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Owen 1990 (Continued)
Other bias Unclear risk Due to the low quality of the reporting in
this study it is unclear whether the study is
at risk from any other forms of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and doctors were not blinded
to allocation, however it is not stated
whether other key study personnel were
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not reported whether or not the out-
come assessment was carried out blind
Rahlfs 1976
Methods RCT, double blind, parallel study, 2 weeks duration
Participants Setting; general practice, Germany
Number of participants; 71 patients treated (number of patients randomised not clearly
stated), 63 patients included in analysis
Recruitment methods; patients presenting in general practice with suspected IBS
Diagnosis of IBS; Clinical diagnosis plus completion of detailed questionnaire
Mean age (of treated patients); 43.8 years
Gender (of treated patients); 50.8% female
Duration of symptoms > 14 days
Interventions 1. 0.1% asafoetida alcohol solution, 6 x 5 drops daily
2. 0.1% asafoetida alcohol solution + 0.01% nux vomica alcohol solution, 6 x 5 drops
daily
3. placebo, 45% alcohol solution, 6 x 5 drops daily
Outcomes Self assessment on a 3 point scale; no or negligible improvement, more than half im-
proved, free of symptoms measured on day 8 and day 15 of the study
Time to recovery assessed by the patient reporting the day they felt considerable im-
provement
Freiburg Personality Inventory
Notes Analysed participant data were fairly well described, but a lot of pre-randomisation and
pre-analysis data were missing
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk A chance code was used for the randomi-
sation, the exact nature of which was not
reported
Therefore the risk of bias cannot be deter-
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Rahlfs 1976 (Continued)
mined
Allocation concealment (selection bias) Low risk Medication was provided in sequentially
numbered drug containers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition, some
reasons for attrition are given, details of al-
location are not always given
Selective reporting (reporting bias) Unclear risk Insufficient informationwas provided to be
able to judge whether the study was at risk
from selective reporting
Other bias Unclear risk Insufficient information was provided to
assess whether the study was at risk from
any other bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and recruiting doctors
were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome as-
sessment was carried out blind
Rahlfs 1979
Methods RCT, double blind, parallel study, 2 weeks duration
Participants Setting; general practice, Germany
Number of participants; 119 patients treated (number of participants randomised not
clearly stated), 89 patients included in analysis
Recruitment methods; patients presenting in general practice with suspected IBS
Diagnosis of IBS; Clinical diagnosis plus completion of detailed questionnaire
Mean age (of patients included in analysis, ages of those not included not stated); 42.5
years
Gender (of those included in analysis, gender of those not included not stated); 68.5%
female
Duration of symptoms > 14 days
Interventions 1. 0.1% asafoetida alcohol solution, 6 x 5 drops daily
2. placebo, 45% alcohol solution, 6 x 5 drops daily
Outcomes Self assessment on a 4 point scale; worsening of symptoms, no or negligible improvement,
more than half improved, free of symptoms, measured on day 8 and day 15 of the study
Time to recovery assessed by the patient reporting the day they felt considerable im-
provement
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Rahlfs 1979 (Continued)
Notes Analysed participant data were fairly well described, but a lot of pre-randomisation and
pre-analysis data were missing
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Although it was reported that this was a
randomised trial no details were given as to
how randomisation was achieved
Allocation concealment (selection bias) Low risk Medication was provided in sequentially
numbered drug containers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Incomplete outcome data, reasons formiss-
ing data, and how incomplete outcome
data were addressed was not clearly de-
scribed
Selective reporting (reporting bias) High risk The inclusion and exclusion criteria were
applied in a variable manner, some people
that were subsequently found not to meet
the exclusion and inclusion criteria were re-
moved from the analysis
However people who did not meet the in-
clusion criteria for age, being too old were
still included in the analysis
This leaves the study at risk of bias due to
selective reporting
Other bias Unclear risk Due to the low quality of the reporting it
was unclear whether the study was at risk
from any other forms of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and doctors were blinded to
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome as-
sessment was carried out blind to treatment
allocation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aleem 2000 Discussion piece and not a randomised controlled trial, cohort or case-control study
Anonymous 2005 An initial reading of this Italian article revealed it to be discussing a meta analysis by Shang 2005
Therefore a full translation was not conducted
Anonymous 2009 Discussion piece and not a randomised controlled trial, cohort or case-control study
Bhagat 2010 Case report (n = 1) of homeopathic treatment for IBS
Bhattacharjee 2010 The article was a discussion on the different homeopathic remedies used for the treatment of IBS
Chimthanawala 2004 Case report (n = 2) of homeopathic treatment for IBS
Diamond 2005 A discussion on the use of complementary therapies for the treatment of gastroenterological problems
Feldhaus 2000 This was a discussion piece on the treatment of IBS
Gamble 2007 Discussion of a potentially new way of assessing and treating IBS, from a homeopathic perspective, using
two cases as an example
Gebhardt Discussion on homeopathic treatment for IBS, not a randomised controlled trial, cohort or case-control
study
Gray 1998 This study was a case series of 25 patients with no comparator group
Greeson 2008 Non-randomised observational study of outcomes for patients attending a integrative medical centre where
homeopathy was only one of the treatments offered
Innes 2000 This study was a case series (n = 20) with no comparator group
Jagose A Case report (n = 1) of homeopathic treatment for IBS
Jones 1996 A discussion of the homeopathic treatment of IBS, illustrated by three cases
Jones 1997 Discussion piece on homeopathic treatment of IBS
Jones 1999 Case report study of a woman with IBS treated with homeopathy
Krishendu 2010 A discussion of the different homeopathic remedies used for the treatment of IBS
Lobo 2000 Case report (n = 1) on homeopathic treatment of IBS
Master 2008 Discussion piece on homeopathy for IBS
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(Continued)
Mohan 2006 Case report (n = 2) of IBS treated with homeopathy
Pinto 1999 A selection of case reports on homeopathic treatment for a variety of conditions
Slade 2003 Case report (n = 1) of homeopathic treatment of ulcerative colitis
Turner 2008 Discussion of homeopathic treatment of IBS, illustrated by eight case histories
White 1999 Discussion of homeopathic treatment for IBS, not a randomised controlled trial, cohort or case-control study
Characteristics of ongoing studies [ordered by study ID]
Peckham 2012
Trial name or title Homeopathy for irritable bowel syndrome (HIBS)
Methods Three arm, parallel group non-blinded randomised controlled trial
Those randomised to the active treatment arms will be offered up to five one hour consultations, with a
consultation every five weeks
Outcomes will be collected at baseline, 26 weeks and 52 weeks
Participants Setting: Hospital outpatient, UK
Recruitment methods: GP database recruitment, consultant gastroenterologist in secondary care
Diagnosis of IBS: diagnosed according to the Rome III criteria, potentially eligible participants were asked to
complete a questionnaire which included the Rome III criteria for IBS
Participants had to score a minimum of 100 on the IBS-SSS to be eligible to take part in the trial
Minmium duration of IBS: 3 months
Interventions 1. Individualised homeopathic treatment plus usual care
2. Supportive listening plus usual care
3. Usual care alone
Outcomes IBS-SSS, EQ-5D, HADS
Starting date January 2011
Contact information
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Homeopathy compared to usual care or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global improvement - patients
who improved
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Asafoetida only 2 129 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [1.18, 2.18]
1.2 Asafoetida + nux vom 1 42 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.80, 2.15]
2 Feeling unwell 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Homeopathy compared to usual care or placebo, Outcome 1 Global
improvement - patients who improved.
Review: Homeopathy for treatment of irritable bowel syndrome
Comparison: 1 Homeopathy compared to usual care or placebo
Outcome: 1 Global improvement - patients who improved
Study or subgroup Homeopathy Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asafoetida only
Rahlfs 1976 14/21 12/23 39.2 % 1.28 [ 0.78, 2.10 ]
Rahlfs 1979 32/42 18/43 60.8 % 1.82 [ 1.23, 2.69 ]
Subtotal (95% CI) 63 66 100.0 % 1.61 [ 1.18, 2.18 ]
Total events: 46 (Homeopathy), 30 (Placebo)
Heterogeneity: Chi2 = 1.22, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 3.04 (P = 0.0024)
2 Asafoetida + nux vom
Rahlfs 1976 13/19 12/23 100.0 % 1.31 [ 0.80, 2.15 ]
Subtotal (95% CI) 19 23 100.0 % 1.31 [ 0.80, 2.15 ]
Total events: 13 (Homeopathy), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
0.01 0.1 1 10 100
Favours placebo Favours homeopathy
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Analysis 1.2. Comparison 1 Homeopathy compared to usual care or placebo, Outcome 2 Feeling unwell.
Review: Homeopathy for treatment of irritable bowel syndrome
Comparison: 1 Homeopathy compared to usual care or placebo
Outcome: 2 Feeling unwell
Study or subgroup Homeopathy Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Owen 1990 9 1.44 (4.55) 11 1.41 (1.97) 0.03 [ -3.16, 3.22 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-4 -2 0 2 4
Favours usual care Favours homeopathy
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